Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. a Southwest Oncology Group study
Gagliano, R.G.; Panettiere, F.J.; Haas, C.D.; Baker, L.; Hewlett, J.; Stuckey, W.J.; O'Bryan, R.M.; Bottomley, R.; Heilburn, L.K.
Cancer Clinical Trials 4(4): 401-405
1981
ISSN/ISBN: 0190-1206 PMID: 7318121 Document Number: 5282
Two hundred twenty eligible patients with metastatic colorectal carcinoma were treated with a combination of beta-2'-deoxythioguanosine (BTG), plus methyl-CCNU or mitomycin. There was no significant difference in overall response (CR/PR + stable) among fully evaluable patients between the mitomycin plus BTG arm 19/96 (19.7%) and the MeCCNU arm 26/87 (29.8%). Median survival of eligible patients was 19 weeks with mitomycin plus BTG versus 21 weeks with MeCCNU plus BTG: no difference. Median survival of responders (40 weeks) and patients with stable disease (35 weeks) was significantly better than patients with increasing disease (17 weeks): p + 0.001.
Document emailed within 1 workday
